摘要
目的观察阿托伐他汀钙强化治疗不稳定型心绞痛(unstable angina pectoris,UAP)的临床疗效和安全性。方法80例UAP患者完全随机分为强化治疗组和常规对照组各40例,两组均给予常规药物治疗,强化治疗组给予阿托伐他汀钙60mg/d;常规对照组给予阿托伐他汀钙20 mg/d,治疗2周,观察两组UAP发作次数、心电图、血脂、高敏C反应蛋白(hs-CRP)水平以及肝肾功等指标变化。结果治疗后强化治疗组UAP发作次数、低密度脂蛋白(LDL-c)及hs-CRP水平明显低于常规对照组,总有效率明显高于常规对照组,差异均有统计学意义(P<0.05);两组安全性指标差异无统计学意义(P>0.05)。结论大剂量阿托伐他汀钙短期强化治疗与常规剂量比较,强化治疗可有效降低UAP患者心血管事件的发生率,是更有效和更安全的临床治疗选择。
Objective To observe the effects and safety of atorvastatin calcium in the intensive treatment of patients with unstable angina pectoris（UAP）.Methods Eighty UAP patients were randomly divided into intensive treatment and control groups,40 in each group.The two groups were all given conventional drug therapy.The intensive treatment group was treated with atorvastatin calcium 60 mg/d while the control group with atorvastatin calcium 20 mg/d.After 2 weeks of treatment,frequency of UAP,electrocardiogram,blood lipids,high sensitive C reactive protein（hs-CRP） level and liver and kidney function were compared between the two groups.Results The differences in the frequency of UAP the levels of low density lipoprotein and hs-CRP,and total efficiency between the two groups were statistically different（P〈0.05）.There was no significant difference in indexes of safety between the two groups.Conclusion Large dose atorvastatin calcium can effectively reduce the incidence of cardiovascular events in patients with UAP.It is a more effective and safe clinical treatment option.
出处
《实用医院临床杂志》
2015年第4期83-85,共3页
Practical Journal of Clinical Medicine
关键词
不稳定型心绞痛
阿托伐他汀钙
强化治疗
安全性
Unstable angina pectoris
Atorvastatin calcium
Intensive treatment
Safety
